Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KAN-ONCO-06
- Development stage
- Preclinical
- Lead developer
- Kantify
- Modality
- Small Molecules
01
Overview
KAN-ONCO-06 is a preclinical small molecule drug candidate discovered using the Sapian AI platform by Kantify in collaboration with the Children's Hospital Zurich. It is designed to address Diffuse Intrinsic Pontine Glioma (DIPG), a rare and aggressive pediatric brain tumor, by targeting multiple novel oncology pathways. The program is currently in the early stages of development, encompassing hit discovery and lead optimization. As an AI-discovered compound, it represents a targeted approach to identifying therapeutic interventions for high-grade gliomas that have historically lacked effective treatment options.
Beyond the preview
Go deeper on KAN-ONCO-06.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KAN-ONCO-06.